Waiting for update- soon
Imo+dyor.
ATL1101
ATL1101 is a second generation antisense drug that targets the insulin-like growth factor I receptor, and has been shown in previously conducted animal studies to suppress human prostate tumour growth.
The drug has potential applications in various other cancers as well as indications in certain eye diseases, where second generation antisense drugs have shown clinical benefits.
ATL1101 is potentially positioned to move into clinical development in prostate cancer patients.
- Forums
- ASX - By Stock
- PER
- ANP price movement
ANP price movement, page-407
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.7¢ |
Change
0.003(3.57%) |
Mkt cap ! $78.43M |
Open | High | Low | Value | Volume |
8.4¢ | 8.7¢ | 8.4¢ | $72.99K | 855.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 398595 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 0.084 |
3 | 212500 | 0.083 |
2 | 106250 | 0.080 |
2 | 125578 | 0.079 |
2 | 30620 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 398595 | 1 |
0.088 | 400000 | 1 |
0.089 | 135000 | 2 |
0.090 | 794374 | 5 |
0.092 | 50000 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online